Figure 1From: Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology LS mean SIB total score change from baseline by Visit (observed cases) and at primary end point (Week 24-LOCF) in patients with MMSE scores of 0-20 (primary analysis; A) and 0-16 (post hoc analysis; B).Back to article page